Operations

FDA cites systemic failures in how the company tracked and reported adverse drug events across several of its medicines, including semaglutide.

Ron Lanton, Senior Partner & Global Strategist, Lanton, Lanton & Sosa Law PLLC, notes FDA’s single-trial approval pathway may accelerate development, but manufacturers face heightened litigation risk, pricing uncertainty and safeguards.

The business and market models drugmakers must continually adapt to stay competitive as 2026 progresses.

In this Pharmaceutical Executive Academy discussion, Najat Khan, PhD, CEO of Recursion Pharmaceuticals and former chief data science officer at J&J, explores the intersection of AI, pharma, and patient care — and the strategic pivots necessary to drive measurable and lasting gains across the value chain.

Novo Nordisk is investing to expand its Athlone, Ireland facility, aiming to boost global manufacturing capacity for oral GLP-1 treatments.

Sarepta Therapeutics begins a CEO succession process, while Rivus Pharmaceuticals appoints a new chief executive to advance its late-stage pipeline in MASH, obesity, and cardiometabolic disease.

Alkermes announces that longtime CEO Richard Pops plans to step down on July 31, 2026, with his successor already set to step into the role on August 1.

Britain’s MHRA intensifies enforcement against illegal weight-loss drugs, seizing nearly 2,000 doses and equipment amid rising global demand for obesity treatments.

AbbVie invests $380 million to build two new API manufacturing facilities in North Chicago while Bora Pharmaceuticals Co., Ltd. and GSK have renewed a five-year global manufacturing partnership.

Hims & Hers has agreed to acquire Australia-based Eucalyptus for up to $1.15 billion, expanding its international footprint across Australia, Canada, Germany and the U.K.

HHS Secretary Robert F. Kennedy Jr. reorganized senior leadership at the department to streamline management and advance the administration’s health policy priorities.

Following the decisions=, the European Commission decided to close a long-running antitrust investigation

Eli Lilly's $1.5 billion pre-launch inventory of orforglipron signals an aggressive manufacturing strategy aimed at avoiding supply shortages and capturing early share in the competitive obesity market.

Sanofi named Belén Garijo as its next CEO, signaling a leadership shift aimed at sharpening execution and R&D productivity as the company moves beyond the strategic overhaul of the past six years.

Kim Boericke, CEO, Veristat, touches on how early strategic consulting, data analytics, and automation help optimize trial design, define realistic patient populations, and generate faster insights.

Yerem Yeghiazarians founder, CEO of Soley Therapeutics, talks about how drug discovery is a team effort, noting that success requires a strong vision, hands-on leadership, and a talented staff.

Kim Boericke, CEO, Veristat, notes that advancing women into STEM leadership requires strong advocacy from senior leaders, strategic career planning, and building visibility through cross-functional collaboration and networking.

Dave Carey, CEO, Preceptis Medical and Michael Monovoukas, CEO, co-founder, AcuityMD note the importance of shifting ear tube procedures into the office, reducing anesthesia risk, and how AI-driven data and adaptive commercial strategies are becoming critical to scaling new medtech innovations.

The facility builds on Eli Lilly's $50 Billion investment strategy to strengthen the company's domestic manufacturing capabilities.

How to optimize a pharma location strategy in unheralded but rich regions for biotech talent around the world.

Taking a more strategic, data-driven approach to tail spend can transform procurement from a fragmented cost center into a source of compliance strength, operational efficiency, and greater supply chain confidence.

Persistent blood shortages compounded by widespread laboratory staffing burnout and vacancies are straining transfusion medicine, making investment in lab workforces critical to safeguarding patient access to lifesaving blood supplies.

The acquisition includes several gummy products that are expected to begin launching in 2026.

The AI dilemma facing biopharma—and what’s at risk.

A comparison of 2024 and 2025 bio/pharma employment survey results indicates that industry professionals face eroding security, polarized satisfaction, and rising attrition risk.